Function of HNF1 in the pathogenesis of diabetes

Expert Review of Endocrinology and Metabolism

Volumn 3, Issue 3, 2008, Pages 391-403

  Rhoads, David B ^a   Levitsky, Lynne L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Maturity onset diabetes of the young; MODY; Mutation; Phenotype; Protein structure; Tertiary; Transcription factor

Indexed keywords

GENE PRODUCT; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MATURITY ONSET DIABETES OF THE YOUNG 2 PROTEIN; MATURITY ONSET DIABETES OF THE YOUNG 3 PROTEIN; MATURITY ONSET DIABETES OF THE YOUNG 5 PROTEIN; MATURITY ONSET DIABETES OF THE YOUNG PROTEIN; NEUROGENIC DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IPF1; UNCLASSIFIED DRUG;

ANIMAL CELL CULTURE; CELL MATURATION; DELETION MUTANT; DIMERIZATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DNA BINDING; FRAMESHIFT MUTATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE STRUCTURE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INSULIN RELEASE; INSULIN RESISTANCE; MATURITY ONSET DIABETES MELLITUS; METABOLIC REGULATION; MISSENSE MUTATION; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONSENSE MUTATION; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 55649104950     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.3.3.391     Document Type: Review

References (149)

1. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med. 345, 971-980 (2001).
2. Vaxillaire M, Froguel P. Genetic basis of maturity-onset diabetes of the young. Endocrinol. Metab. Clin. North Am. 35, 371-384 (2006).
3. Gupta RK, Kaestner KH. HNF-4α: From MODY to late-onset Type 2 diabetes. Trends. Mol. Med. 10, 521-524 (2004).
4. Bonnycastle LL, Willer CJ, Conneely KN et al. Common variants in maturity-onset diabetes of the young genes contribute to risk of Type 2 diabetes in Finns. Diabetes 55, 2534-2540 (2006).
5. Shaat N, Karlsson E, Lernmark A et al. Common variants in MODY genes increase the risk of gestational diabetes mellitus. Diabetologia 49, 1545-1551 (2006).
6. Yamagata K, Furuta H, Oda N et al. Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature 384, 458-460 (1996).
7. Chen WS, Manova K, Weinstein DC et al. Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev. 8, 2466-2477 (1994).
8. Froguel P, Zouali H, Vionnet N et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N. Engl. J. Med. 328, 697-702 (1993).
9. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic β cell glucokinase in maintaining glucose homeostasis. Cell 83, 69-78 (1995).
10. Terauchi Y, Sakura H, Yasuda K et al. Pancreatic β-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J. Biol. Chem. 270, 30253-30256 (1995).
11. Yamagata K, Oda N, Kaisaki PJ et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455-458 (1996).
12. Lee YH, Sauer B, Gonzalez FJ. Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1α knockout mouse. Mol. Cell. Biol. 18, 3059-3068 (1998).
13. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset Type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet. 17. 138-139 (1997).
14. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371, 606-609 (1994).
15. Horikawa Y, Iwasaki N, Hara M et al. Mutation in hepatocyte nuclear factor-1β gene (TCF2) associated with MODY. Nat. Genet. 17, 384-385 (1997).
16. Barbacci E, Reber M, Ott MO, Breillat C, Huetz F, Cereghini S. Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. Development 126, 4795-4805 (1999).
17. Coffinier C, Thepot D, Babinet C, Yaniv M, Barra J. Essential role for the homeoprotein vHNF1/HNF1β in visceral endoderm differentiation. Development 126, 4785-4794 (1999).
18. Malecki MT, Jhala US, Antonellis A et al. Mutations in NEUROD1 are associated with the development of Type 2 diabetes mellitus. Nat. Genet. 23, 323-328 (1999).
19. Liu M, Pleasure SJ, Collins AE et al. Loss of BETA2/NeuroD leads to malformation of the dentate gyrus and epilepsy. Proc. Natl Acad. Sci. USA 97, 865-780 (2000).
20. Huang HP, Chu K, Nemoz-Gaillard E, Elberg D, Tsai MJ. Neogenesis of β-cells in adult BETA2/NeuroD-deficient mice. Mol. Eodocrinol. 16, 541-551 (2002).
21. Hattersley AT, Pearson TR. Minireview: Pharmacogenetics and beyond: the interaction of therapeutic response, β-cell physiology, and genetics in diabetes. Endocrinology 147, 2657-2663 (2006).
22. Schuit FC, Huypens P, Heimberg H, Pipeleers DG. Glucose sensing in pancreatic β-cells: A model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 50, 1-11 (2001).
23. Navas MA, EJ Munoz-Elias Kim J, Shih D, Stoffel M. Functional characterization of the MODY1 gene mutations HNF4(R127W), HNF4(V255M), and HNF4(E276Q). Diabetes 48, 1459-1465 (1999).
24. Vaxillaire M, Abderrahmani A, Boutin P et al. Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations. J. Biol. Chem. 274, 35639-35646 (1999).
25. Tomura H, Nishigori H, Sho K. Yamagata K, Inoue I, Takeda J. Loss-of-function and dominant-negative mechanisms associated with hepatocyte nuclear factor-1β mutations in familial Type 2 diabetes mellitus. J. Biol. Chem. 274, 12975-12978 (1999).
26. Furuta H, Furuta M, Sanke T et al. Nonsense and missense mutations in the human hepatocyte nuclear factor-1β gene (TCF2) and their relation to Type 2 diabetes in Japanese. J. Clin. Endocrinol. Metab. 87, 3859-3863 (2002).
27. Neve B, ME Fernandez-Zapico V Ashkenazi-Katalan et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic β cell function. Proc. Natl Acad. Sci. USA 102, 4807-4812 (2005).
28. Raeder H, Johansson S, Holm PI et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat. Genet. 38, 54-62 (2006).
29. Mendel DB, Crabtree GR. HNF-1, a member of a novel class of dimerizing homeodomain proteins. J. Biol. Chem. 266, 677-680 (1991).
30. Cereghini S, Raymondjean M, Carranca AG, Herbomel P, Yaniv M. Factors involved in control of tissue-specific expression of albumin gene. Cell 50, 627-638 (1987).
31. Courtois G, Baumhueter S, Crabtree GR. Purified hepatocyte nuclear factor 1 interacts with a family of hepatocyte-specific promoters. Proc. Natl Acad. Sci. USA 85, 7937-7941 (1988).
32. Frain M, Swart G, Monaci P et al. The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 59, 145-157 (1989).
33. De Simone V, De Magistris L, Lazzaro D et al. LFB3, a heterodimer-forming homeoprotein of the LFB1 family, is expressed in specialized epithelia. EMBO J. 10, 1435-1443 (1991).
34. Bach I, Mattei MG, Cereghini S, Yaniv M. Two members of an HNF1 homeoprotein family are expressed in human liver. Nucleic Acids Res. 19, 3553-3559 (1991).
35. Mendel DB, Hansen LP, Graves MK, Conley PB, Crabtree GR. HNF-1α and HNF-1β (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro. Genes Dev. 5, 1042-1056 (1991).
36. Nicosia A, Monaci P, Tomei L et al. A myosin-like dimerization helix and an extra-large homeodomain are essential elements of the tripartite DNA binding structure of LFB1. Cell 61, 1225-1236 (1990).
37. Rey-Campos J, Chouard T, Yaniv M, Cereghini S. vHNF1 is a homeoprotein that activates transcription and forms heterodimers with HNF1. EMBO J. 10, 1445-1457 (1991).
38. Ringeisen F, J Rey-Campos Yaniv M. The transactivation potential of variant hepatocyte nuclear factor 1 is modified by alternative splicing. J. Biol. Chem. 268, 25706-25711 (1993).
39. Serfas MS, Tyner AL. HNF-1α and HNF-1β expression in mouse intestinal crypts. Am. J. Physiol. 265, G506-G513 (1993).
40. Miquerol L, Lopez S, Cartier N, Tulliez M, Raymondjean M, Kahn A. Expression of the L-type pyruvate kinase gene and the hepatocyte nuclear factor 4 transcription factor in exocrine and endocrine pancreas. J. Biol. Chem. 269, 8944-8951 (1994).
41. Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 10, 267-282 (1996).
42. Hagenfeldt-Johansson KA, Herrera PL, Wang H, Gjinovci A, Ishihara H, Wollheim CB. β-cell-targeted expression of a dominant-negative hepatocyte nuclear factor-1α induces a maturity-onset diabetes of the young (MODY)3-like phenotype in transgenic mice. Endocrinology 142, 5311-5320 (2001).
43. Maestro MA, Boj SF, Luco RF et al. Hnf6 and Tcf2 (MODY5) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas. Hum. Mol. Genet. 12, 3307-3314 (2003).
44. Sirbu IO, Gresh L, Barra J, Duester G. Shifting boundaries of retinoic acid activity control hindbrain segmental gene expression. Development 132, 2611-2622 (2005).
45. Vaulont S, Kahn A. Transcriptional control of metabolic regulation genes by carbohydrates. FASEB J. 8, 28-35 (1994).
46. Tronche F, Ringeisen F, Blumenfeld M, Yaniv M, Pontoglio M. Analysis of the distribution of binding sites for a tissue-specific transcription factor in the vertebrate genome. J. Mol. Biol. 266, 231-245 (1997).
47. Baumhueter S, Courtois G, Morgan JG, Crabtree GR. The role of HNF-1 in liver-specific gene expression. Ann. NY Acad. Sci. 557, 272-279 (1989).
48. Pontoglio M, Pausa M, Doyen A, Viollet B, Yaniv M, Tedesco F. Hepatocyte nuclear factor 1α controls the expression of terminal complement genes. J. Exp. Med. 194, 1683-1689 (2001).
49. Sakaguchi T, Gu X, Golden HM, Suh E, Rhoads DB, Reinecker HC. Cloning of the human claudin-2 5′-flanking region revealed a TATA-less promoter with conserved binding sites in mouse and human for caudal-related homeodomain proteins and hepatocyte nuclear factor-1α. J. Biol. Chem. 277, 21361-21370 (2002).
50. Koffler LD, Fernstrom MJ, Akiyama TE, Gonzalez FJ, Ruch RJ. Positive regulation of connexin32 transcription by hepatocyte nuclear factor-1α. Arch. Biochem. Biophys. 407, 160-167 (2002).
51. Torres-Padilla ME, Fougere-Deschatrette C, Weiss MC. Expression of HNF4α isoforms in mouse liver development is regulated by sequential promoter usage and constitutive 3′ end splicing. Mech. Dev. 109, 183-193 (2001).
52. Hatzis P, Talianidis I. Regulatory mechanisms controlling human hepatocyte nuclear factor 4α gene expression. Mol. Cell. Biol. 21, 7320-7330 (2001).
53. Zhong W, Sladek FM, Darnell JE Jr. The expression pattern of a Drosophila homolog to the mouse transcription factor HNF-4 suggests a determinative role in gut formation. EMBO J. 12, 537-544 (1993).
54. Poll AV, Pierreux CE, Lokmane L et al. A vHNF1/TCF2-HNF6 cascade regulates the transcription factor network that controls generation of pancreatic precursor cells. Diabetes 55, 61-69 (2006).
55. Hay CW, Docherty K. Comparative analysis of insulin gene promoters: implications for diabetes research. Diabetes 55, 3201-3213 (2006).
56. Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J. Am. Soc. Nephrol. 11 (Suppl. 16), S140-S143 (2000).
57. Wang H, K Hagenfeldt-Johansson Otten LA, Gauthier BR, Herrera PL, Wollheim CB. Experimental models of transcription factor-associated maturity-onset diabetes of the young. Diabetes 51 (Suppl. 3), S333-S342 (2002).
58. Giuffrida FM, Reis AF. Genetic and clinical characteristics of maturity-onset diabetes of the young. Diabetes Obes. Metab. 7, 318-326 (2005).
59. Timsit J, C Bellanne-Chantelot D Dubois-Laforgue Velho G. Diagnosis and management of maturity-onset diabetes of the Young. Treat. Endocrinol. 4, 9-18 (2005).
60. Olek K. Maturity-onset diabetes of the young: An update. Clin. Lab. 52, 593-598 (2006).
61. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1α (HNF1A) and 4α (HAF4A) in maturity-onset diabetes of the young. Hum. Mutat. 27, 854-869 (2006).
62. Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1β. Hum. Mol. Genet. 8, 2001-2008 (1999).
63. Cereghini S, Ott MO, Power S, Maury M. Expression patterns of vHNF1 and HNF1 homeoproteins in early postimplantation embryos suggest distinct and sequential developmental roles. Development 116, 783-797 (1992).
64. Ueda H, Ikegami H, Kawaguchi Y et al. Genetic analysis of late-onset Type 2 diabetes in a mouse model of human complex trait. Diabetes 48, 1168-1174 (1999).
65. Herr W, Cleary MA. The POU domain: Versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. Genes Dev. 9, 1679-1693 (1995).
66. Sourdive DJ, Chouard T, Yaniv M. The HNF1 C-terminal domain contributes to transcriptional activity and modulates nuclear localisation. C. R. Acad Sci. III. 316, 385-394 (1993).
67. Chouard T, Blumenfeld M, Bach I, Vandekerckhove J, Cereghini S, Yaniv M. A distal dimerization domain is essential for DNA-binding by the atypical HNF1 homeadomain. Nucleic Acids Res. 18, 5853-5863 (1990).
68. Rose RB, Bayle JH, Endrizzi JA, Cronk JD, Crabtree GR, Alber T. Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1α. Nat. Struct. Biol. 7, 744-748 (2000).
69. Narayana N, Hua Q, Weiss MA. The dimerization domain of HNF-1α: structure and plasticity of an intertwined four-helix bundle with application to diabetes mellitus. J. Mol. Biol. 310, 635-658 (2001).
70. Mendel DB, Khavari PA, Conley PB et al. Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein. Science 254, 1762-1767 (1991).
71. Citron BA, Davis MD, Milstien S et al. Identity of 4α-carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins. Proc. Natl Acad. Sci. USA 89, 11891-11894 (1992).
72. Pomerantz JL, Sharp PA. Homeodomain determinants of major groove recognition. Biochemistry 33, 10851-10858 (1994).
73. Ceska TA, Lamers M, Monaci P, Nicosia A, Cortese R, Suck D. The x-ray structure of an atypical homeodomain present in the rat liver transcription factor LFB1/HNF1 and implications for binding DNA. EMBO J. 12, 1805-1810 (1993).
74. Tomei L, Cortese R, De Francesco R. A POU-A related region dictates DNA binding specificity of LFB1/HNF1 by orienting the two XL-homeodomains in the dimer. EMBO J. 11, 4119-4129 (1992).
75. Chi YI, Frantz JD, Oh BC, Hansen L, Dhe-Paganon S, Shoelson SE. Diabetes mutations delineate an atypical POU domain in HNF-1α. Mol. Cell 10, 1129-1137 (2002).
76. Lu P, Rha GB, Chi YI. Structural basis of disease-causing mutations in hepatocyte nuclear factor 1β. Biochemistry 46, 12071-12080 (2007).
77. Deleage G, Combet C, Blanchet C, Geourjon C. ANTHEPROT: An integrated protein sequence analysis software with client/server capabilities. Comput. Biol. Med. 31, 259-267 (2001).
78. Sigler PB. Transcriptional activation. Acid blobs and negative noodles. Nature 333, 210-212 (1988).
79. Bjorkhaug L, Bratland A, Njolstad PR, Molven A. Functional dissection of the HNF-1α transcription factor: A study an nuclear localization and transcriptional activation. DNA Cell Biol. 24. 661-669 (2005).
80. Sock E, Enderich J, Rosenfeld MG, Wegner M. Identification of the nuclear localization signal of the POU domain protein Tst-1/Oct6. J. Biol. Chem. 271, 17512-17518 (1996).
81. Holloway JM, Szeto DP, Scully KM, Glass CK, Rosenfeld MG. Pit-1 binding to specific DNA sites as a monomer or dimer determines gene-specific use of a tyrosine-dependent synergy domain. Genes Dev. 9, 1992-2006 (1995).
82. Mullis PE. Genetics of growth hormone deficiency. Endocrinol. Metab. Clin. North Am. 36, 17-36 (2007).
83. Soutoglou E, Viollet B, Vaxillaire M, Yaniv M, Pontoglio M, Talianidis I. Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J. 20, 1984-1992 (2001).
84. Carriere V, Lacasa M, Rousset M. Activity of hepatocyte nuclear factor 1α and hepatocyte nuclear factor 1β isoforms is differently affected by the inhibition of protein phosphatases 1/2A. Biochem. J. 354, 301-308. (2001).
85. Bach I, Yaniv M. More potent transcriptional activators or a transdominant inhibitor of the HNF1 homeoprotein family are generated by alternative RNA processing. EMBO J. 12, 4229-4242 (1993).
86. Harries LW, Ellard S, Stride A, Morgan NG, Hattersley AT. Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1α show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum. Mol. Genet. 15, 2216-2224 (2006).
87. Smale ST. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Biochim. Biophys. Acta 1351, 73-88 (1997).
88. Miura N, Tanaka K. Analysis of the rat hepatocyte nuclear factor (HNF) 1 gene promoter: Synergistic activation by HNF4 and HNF1 proteins. Nucleic Acids Res. 21, 3731-3736 (1993).
89. Jung D, GA Kullak-Ublick. Hepatocyte nuclear factor 1α: A key mediator of the effect of bile acids on gene expression. Hepatology 37, 622-631 (2003).
90. Godart F, Bellanne-Chantelot C, Clauin S et al. Identification of seven novel nucleotide variants in the hepatocyte nuclear factor-1α (TCF1) promoter region in MODY patients. Hum. Mutat. 15, 173-180 (2000).
91. Lockwood CR, Bingham C, Frayling TM. In silico searching of human and mouse genome data identifies known and unknown HNF1 binding sites upstream of β-cell genes. Mol. Genet. Metab. 78, 145-151 (2003).
92. Power SC, Cereghini S. Positive regulation of the vHNF1 promoter by the orphan receptors COUP-TF1/Ear3 and COUP-TFII/Arp1. Mol. Cell Biol. 16, 778-791 (1996).
93. Gragnoli C, Lindner T, Cockburn BN et al. Maturity-onset diabetes of the young due to a mutation in the hepatocyte nuclear factor-4α binding site in the promoter of the hepatocyte nuclear factor-1α gene. Diabetes 46, 1648-1651 (1997).
94. Yoshiuchi I, Yamagata K, Yoshimoto M et al. Analysis of a non-functional HNF-1α (TCF1) mutation in Japanese subjects with familial Type 1 diabetes. Hum. Mutat. 18, 345-351 (2001).
95. Thomas H, Badenberg B, Bulman M et al. Evidence for haploinsufficiency of the human HNF1α gene revealed by functional characterization of MODY3-associated mutations. Biol. Chem. 383, 1691-1700 (2002).
96. Stern E, Strihan C, Potievsky O et al. Four novel mutations, including the first gross deletion in TCF1, identified in HNF-4α, GCK and TCF1 in patients with MODY in Israel. J. Pediatr. Endocrinol. Metab. 20, 909-921 (2007).
97. Ellard S, Thomas K, Edghill EL et al. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia 50, 2313-2317 (2007).
98. Bellanne-Chantelot C, Clauin S, Chauveau D et al. Large genomic rearrangements in the hepatocyte nuclear factor-1β (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young Type 5. Diabetes 54, 3126-3132 (2005).
99. Edghill EL, Oram RA, Owens M et al. Hepatocyte nuclear factor-1β gene deletions a common cause of renal disease. Nephrol. Dial. Transplant 23(2), 627-635 (2007).
100. Harries LW, Hattersley AT, Ellard S. Messenger RNA transcripts of the hepatocyte nuclear factor-1α gene containing premature termination codons are subject to nonsense-mediated decay. Diabetes 53, 500-504 (2004).
101. Iwasaki N, Oda N, Ogata M et al. Mutations in the hepatocyte nuclear factor-1α/MODY3 gene in Japanese subjects with early- and late-onset NIDDM. Diabetes 46, 1504-1508 (1997).
102. Bjorkhaug L, Sagen JV, Thorsby P, Sovik O, Molven A, Njolstad PR. Hepatocyte nuclear factor-1α gene mutations and diabetes in Norway. J. Clin. Endocrinol. Metab. 88, 920-931 (2003).
103. Stride A, Ellard S, Clark P et al. β-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1α mutation carriers. Diabetes Care 28, 1751-1756 (2005).
104. Vesterhus M, Raeder H, Johansson S, Molven A, Njolstad PR. Pancreatic exocrine dysfunction in MODY3. Diabetes Care 31(2), 306-310 (2007).
105. Vaxillaire M, Rouard M, Yamagata K et al. Identification of nine novel mutations in the hepatocyte nuclear factor 1α gene associated with maturity-onset diabetes of the young (MODY3). Hum. Mol. Genet. 6, 583-586 (1997).
106. Bingham C, Ellard S, Nicholls AJ et al. The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1α mutations is a feature of all patients with diabetes and is associated with glucosuria. Diabetes 50, 2047-2052 (2001).
107. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1α gene mutations. Evidence for pharmacogenetics in diabetes. Diabet. Med. 17, 543-545 (2000).
108. Tack CJ, Ellard S, Hattersley AT. A severe clinical phenotype results from the co-inheritance of type 2 susceptibility genes and a hepatocyte nuclear factor-1α mutation. Diabetes Care 23, 424-425 (2000).
109. Malecki MT, Skupien J, Gorczynska-Kosiorz S et al. Renal malformations may be linked to mutations in the hepatocyte nuclear factor-1α (MODY3) gene. Diabetes Care 28, 2774-2776 (2005).
110. Nishigori H, Yamada S, Kohama T et al. Frameshift mutation A263fsinsGG, in the hepatocyte nuclear factor-1β gene associated with diabetes and renal dysfunction. Diabetes 47, 1354-1355 (1998).
111. Kolatsi-Joannou M, Bingham C, Ellard S et al. Hepatocyte nuclear factor-1β: A new kindred with renal cysts and diabetes and gene expression in normal human development. J. Am. Soc. Nephrol. 12, 2175-2180 (2001).
112. Bingham C, Bulman MP, Ellard S et al. Mutations in the hepatocyte nuclear factor-1β gene are associated with familial hypoplastic glomerulocystic kidney disease. Am. J. Hum. Genet. 68, 219-224 (2001).
113. Bellanne-Chantelot C, Chauveau D, Gautier JF et al. Clinical spectrum associated with hepatocyte nuclear factor-1β mutations. Ann. Intern. Med. 140, 510-517 (2004).
114. Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1β and their related phenotypes. J. Med. Genet. 43, 84-90 (2006).
115. Carette C, Vaury C, Barthelemy A et al. Exonic duplication of the hepatocyte nuclear factor-1β gene (transcription factor 2, hepatic) as a cause of maturity onset diabetes of the young type 5. J. Clin. Endocrinol. Metab. 92, 2844-2847 (2007).
116. Edghill EL, Bingham C, Slingerland AS et al. Hepatocyte nuclear factor-1β mutations cause neonatal diabetes and intrauterine growth retardation: Support for a critical role of HNF-1β in human pancreatic development. Diabet. Med. 23, 1301-1306 (2006).
117. Haumaitre C, Fabre M, Cormier S, Baumann C, Delezoide AL, Cereghini S. Severe pancreas hypoplasia and multicystic renal dysplasia in two human fetuses carrying novel HNF1β/MODY5 mutations. Hum. Mol. Genet. 15, 2363-2375 (2006).
118. Kitanaka S, Miki Y, Hayashi Y, Igarashi T. Promoter-specific repression of hepatocyte nuclear factor (HNF)-1β and HNF-1α transcriptional activity by an HNF-1β missense mutant associated with Type 5 maturity-onset diabetes of the young with hepatic and biliary manifestations. J. Clin. Endocrinol. Metab. 89, 1369-1378 (2004).
119. Yoshiuchi I, Yamagata K, Zhu Q et al. Identification of a gain-of-function mutation in the HNF-1β gene in a Japanese family with MODY. Diabetologia 45, 154-155 (2002).
120. Sovik O, Sagen J, Njolstad PR, Nyland H, Myhr KM. Contributions to the MODY5 phenotype. J. Inherit. Metab. Dis. 25. 597-598 (2002).
121. Pearson ER, Badman MK, Lockwood CR et al. Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1α and - 1β mutations. Diabetes Care 27, 1102-1107 (2004).
122. Ek J, Grarup N, Urhammer SA et al. Studies of the variability of the hepatocyte nuclear factor-1β (HNF-1β/TCF2) and the dimerization cofactor of HNF-1 (DCoH/PCBD) genes in relation to Type 2 diabetes mellitus and β-cell function. Hum. Mutat. 18, 356-357 (2001).
123. Manduchi E, Grant GR, He H et al. RAD and the RAD Study-Annotator: an approach to collection, organization and exchange of all relevant information for high-throughput gene expression studies. Bioinformatics 20, 452-459 (2004).
124. Bayle JH, Randazzo F, Johnen G et al. Hyperphenylalaninemia and impaired glucose tolerance in mice lacking the bifunctional DCoH gene. J. Biol. Chem. 277, 28884-28891 (2002).
125. Rose RB, Pullen KE, Bayle JH, Crabtree GR, Alber T. Biochemical and structural basis for partially redundant enzymatic and transcriptional functions of DCoH and DCoH2. Biochemistry 43, 7345-7355 (2004).
126. Ott MO, Rey-Campos J, Cereghini S, Yaniv M. vHNF1 is expressed in epithelial cells of distinct embryonic origin during development and precedes HNF1 expression. Mech. Dev. 36, 47-58 (1991).
127. Coffinier C, Barra J, Babinet C, Yaniv M. Expression of the vHNF1/ HNF1β′ homeoprotein gene during mouse organogenesis. Mech. Dev. 89, 211-213 (1999).
128. Nammo T, Yamagata K, Hamaoka R et al. Expression profile of MODY3/ HNF-1α protein in the developing mouse pancreas. Diabetologia 45, 1142-1153 (2002).
129. Offield MF, Jetton TL, Labosky PA et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122, 983-995 (1996).
130. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. β-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the β-cell phenotype and maturity onset diabetes. Genes Dev. 12, 1763-1768 (1998).
131. Schwitzgebel VM, Scheel DW, Conners JR et al. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. Development 127, 3533-3542 (2000).
132. Gradwohl G, Dierich A, LeMeur M, Guillemot F. Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc. Natl Acad. Sci. USA 97, 1607-1611 (2000).
133. + cells are islet progenitors and are distinct from duct progenitors. Development 129, 2447-2457 (2002).
134. Haumaitre C, Reber M, Cereghini S. Functions of HNF1 family members in differentiation of the visceral endoderm cell lineage. J. Biol. Chem. 278, 40933-40942 (2003).
135. Wang L, Coffinier C, Thomas MK et al. Selective deletion of the Hnf1β (MODY5) gene in β cells leads to altered gene expression and defective insulin release. Endocrinology 145, 3941-3949 (2004).
136. Welters HJ, Senkel S, Klein-Hitpass L et al. Conditional expression of hepatocyte nuclear factor-1β, the maturity-onset diabetes of the young-5 gene product, influences the viability and functional competence of pancreatic β-cells. J. Endocrinol. 190, 171-181 (2006).
137. Pontoglio M, Sreenan S, Roe M et al. Defective insulin secretion in hepatocyte nuclear factor 1α-deficient mice. J. Clin. Invest. 101, 2215-2222 (1998).
138. Dukes ID, Sreenan S, Roe MW et al. Defective pancreatic β-cell glycolytic signaling in hepatocyte nuclear factor-1α-deficient mice. J. Biol. Chem. 273, 24457-24464 (1998).
139. Yamagata K, Nammo T, Moriwaki M et al. Overexpression of dominant-negative mutant hepatocyte nuclear factor-1α in pancreatic β-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced β-cell proliferation, and diabetes. Diabetes 51, 114-123 (2002).
140. Ferrer J. A genetic switch in pancreatic β-cells: Implications for differentiation and haploinsufficiency. Diabetes 51, 2355-2362 (2002).
141. Servitja JM, Ferrer J. Transcriptional networks controlling pancreatic development and β cell function. Diabetologia 47, 597-613 (2004).
142. Furuta H, Iwasaki N, Oda N et al. Organization and partial sequence of the hepatocyte nuclear factor-4α/MODY1 gene and identification of a missense mutation R127W, in a Japanese family with MODY. Diabetes 46, 1652-1657 (1997).
143. Nakhei H, Lingott A, Lemm I, Ryffel GU. An alternative splice variant of the tissue specific transcription factor HNF4α predominates in undifferentiated murine cell types. Nucleic Acids. Res. 26, 497-504 (1998).
144. Kritis AA, Ktistaki E, Barda D, Zannis VI, Talianidis I. An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression. Nucleic Acids Res. 21, 5882-5889 (1993).
145. Boj SF, Parrizas M, Maestro MA, Ferrer J. A transcription factor regulatory circuit in differentiated pancreatic cells. Proc. Natl Acad. Sci. USA 98, 14481-14486 (2001).
146. Bingham C, Ellard S, Allen L et al. Abnormal nephron development associated with a frameshift mutation in the transcription factor hepatocyte nuclear factor-1β. Kidney Int. 57, 898-907 (2000).
147. Iwasaki N, Okabe I, Momoi MY, Ohashi H, Ogata M, Iwamoto Y. Splice site mutation in the hepatocyte nuclear factor-1β gene IVS2nt + 1G > A, associated with maturity-onset diabetes of the young, renal dysplasia and bicornuate uterus. Diabetologia 44, 387-388 (2001).
148. Carbone I, Cotellessa M, Barella C et al. A novel hepatocyte nuclear factor-1β (MODY-5) gene mutation in an Italian family with renal dysfunctions and early-onset diabetes. Diabetologia 45, 153-154 (2002).
149. Bingham C, Ellard S, Cole TR et al. Solitary functioning kidney and diverse genital tract malformations associated with hepatocyte nuclear factor-1β mutations. Kidney Int. 61, 1243-1251 (2002).